Previous 10 | Next 10 |
ABNB, ACHC, ADC, AHT, AIG, AIZ, AKAM, ALR, AMCR, AMD, ANDE, APPH, AQST, ATEN, AYX, BFAM, BGFV, BLKB, BNFT, BNL, BTG, BXC, CGBD, CHCT, CNDT, CNR, COKE, CRK, CRUS, CTSO, CWH, CZR, DENN, DHC, DMTK, EGY, EHTH, EIX, ENLC, ENVA, EQX, EXR, FLGT, FPI, FRSH, GLAD, GLRE, GNW, GPOR, GRBK, HASI, HLF, HRZ...
TransMedics Group (NASDAQ:TMDX) said the U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) to its OCS Heart System for use with organs from donors after circulatory death (DCD). The company noted that the approval could expand the pool of eligible donor hearts in t...
TransMedics Receives FDA PMA Approval of OCS™ DCD Heart Indication PR Newswire ANDOVER, Mass. , April 28, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplan...
TransMedics to Report First Quarter 2022 Financial Results on May 3, 2022 PR Newswire ANDOVER, Mass. , April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplan...
TransMedics Announces the Presentation of New OCS™ Heart and OCS™ Lung Clinical Data at the International Society of Heart and Lung Transplantation 2022 Annual Meeting PR Newswire ANDOVER, Mass. , April 19, 2022 /PRNewswire/ -- TransMedics Group, In...
TransMedics to Present at the Oppenheimer's 32nd Annual Healthcare Conference PR Newswire ANDOVER, Mass. , March 1, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transp...
Gainers: Indonesia Energy Corporation (NYSE:INDO) +65%. Camber Energy (NYSE:CEI) +40%. South Jersey Industries (NYSE:SJI) +40%. Post Holdings (NYSE:POST) +34%. Lantheus Holdings (NASDAQ:LNTH) +33%. Imperial Petroleum (NASDAQ:IMPP) +30%. Cyren (NASDAQ:CYRN) +28%. TransMedics Group (NASDAQ:TMDX...
TransMedics (TMDX +21.6%) shares have added more than a fifth in morning hours Thursday after the med-tech company posted a strong revenue beat for Q4 2021, recording what could be the highest in its earnings history. Revenue for the quarter climbed ~27% YoY to $9.7M mainly driven by the...
Transmedics Group, Inc. (TMDX) Q4 2021 Earnings Conference Call February 23, 2022, 17:00 ET Company Participants Brian Johnston - Gilmartin Group Waleed Hassanein - Founder, MD, CEO, President & Director Stephen Gordon - CFO. Treasurer & Secretary Conference Call Participants William ...
TransMedics Group press release (NASDAQ:TMDX): Q4 GAAP EPS of -$0.46 misses by $0.03. Revenue of $9.7M (+27.3% Y/Y) beats by $2.17M. 2022 Outlook: TransMedics expects net revenue for the full-year 2022 to be in the range of $49 million to $55 million, which represents 62% to 82% growth compar...
News, Short Squeeze, Breakout and More Instantly...
TransMedics Group Inc. Company Name:
TMDX Stock Symbol:
NYSE Market:
TransMedics Group Inc. Website:
TransMedics to Report Second Quarter 2024 Financial Results on July 31, 2024 PR Newswire ANDOVER, Mass. , July 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant...
2024-07-04 23:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Shares of TransMedics Group, Inc. (NASDAQ: TMDX) traded at a new 52-week high today and are currently trading at $139.5. So far today, approximately 249.23k shares have been exchanged, as compared to an average 30-day volume of 655.52k shares. TransMedics Group, Inc., a commercial-stage medic...